Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2008 | 1 |
2011 | 2 |
2012 | 1 |
2014 | 1 |
2015 | 2 |
2016 | 2 |
2024 | 0 |
Search Results
6 results
Results by year
Filters applied: . Clear all
Page 1
Is the focus moving toward a combination of targeted drugs?
Best Pract Res Clin Haematol. 2008 Dec;21(4):629-37. doi: 10.1016/j.beha.2008.08.003.
Best Pract Res Clin Haematol. 2008.
PMID: 19041602
Free PMC article.
Review.
Phase 1 trial of carfilzomib (PR-171) in combination with vorinostat (SAHA) in patients with relapsed or refractory B-cell lymphomas.
Holkova B, Kmieciak M, Bose P, Yazbeck VY, Barr PM, Tombes MB, Shrader E, Weir-Wiggins C, Rollins AD, Cebula EM, Pierce E, Herr M, Sankala H, Hogan KT, Wan W, Feng C, Peterson DR, Fisher RI, Grant S, Friedberg JW.
Holkova B, et al.
Leuk Lymphoma. 2016;57(3):635-43. doi: 10.3109/10428194.2015.1075019. Epub 2015 Oct 12.
Leuk Lymphoma. 2016.
PMID: 26284612
Free PMC article.
Clinical Trial.
Item in Clipboard
LBH-589 (panobinostat) potentiates fludarabine anti-leukemic activity through a JNK- and XIAP-dependent mechanism.
Rosato R, Hock S, Dent P, Dai Y, Grant S.
Rosato R, et al.
Leuk Res. 2012 Apr;36(4):491-8. doi: 10.1016/j.leukres.2011.10.020. Epub 2011 Nov 8.
Leuk Res. 2012.
PMID: 22074700
Free PMC article.
Item in Clipboard
A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma.
Holkova B, Zingone A, Kmieciak M, Bose P, Badros AZ, Voorhees PM, Baz R, Korde N, Lin HY, Chen JQ, Herrmann M, Xi L, Raffeld M, Zhao X, Wan W, Tombes MB, Shrader E, Weir-Wiggins C, Sankala H, Hogan KT, Doyle A, Annunziata CM, Wellons M, Roberts JD, Sullivan D, Landgren O, Grant S.
Holkova B, et al.
Clin Cancer Res. 2016 Mar 1;22(5):1067-75. doi: 10.1158/1078-0432.CCR-15-1076. Epub 2015 Oct 7.
Clin Cancer Res. 2016.
PMID: 26446942
Free PMC article.
Clinical Trial.
Item in Clipboard
Phase I trial of bortezomib (PS-341; NSC 681239) and alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory B-cell neoplasms.
Holkova B, Perkins EB, Ramakrishnan V, Tombes MB, Shrader E, Talreja N, Wellons MD, Hogan KT, Roodman GD, Coppola D, Kang L, Dawson J, Stuart RK, Peer C, Figg WD Sr, Kolla S, Doyle A, Wright J, Sullivan DM, Roberts JD, Grant S.
Holkova B, et al.
Clin Cancer Res. 2011 May 15;17(10):3388-97. doi: 10.1158/1078-0432.CCR-10-2876. Epub 2011 Mar 29.
Clin Cancer Res. 2011.
PMID: 21447728
Free PMC article.
Clinical Trial.
Item in Clipboard
Phase I trial of bortezomib (PS-341; NSC 681239) and "nonhybrid" (bolus) infusion schedule of alvocidib (flavopiridol; NSC 649890) in patients with recurrent or refractory indolent B-cell neoplasms.
Holkova B, Kmieciak M, Perkins EB, Bose P, Baz RC, Roodman GD, Stuart RK, Ramakrishnan V, Wan W, Peer CJ, Dawson J, Kang L, Honeycutt C, Tombes MB, Shrader E, Weir-Wiggins C, Wellons M, Sankala H, Hogan KT, Colevas AD, Doyle LA, Figg WD, Coppola D, Roberts JD, Sullivan D, Grant S.
Holkova B, et al.
Clin Cancer Res. 2014 Nov 15;20(22):5652-62. doi: 10.1158/1078-0432.CCR-14-0805. Epub 2014 Sep 23.
Clin Cancer Res. 2014.
PMID: 25248382
Free PMC article.
Clinical Trial.
Item in Clipboard
Cite
Cite